Methotrexate Shows Promise for Pulmonary Sarcoidosis

A new clinical trial finds methotrexate may be a noninferior alternative to prednisone for newly diagnosed patients.

Updated on Oct. 31, 2026 in Asthma

Clean laboratory test tubes containing clear liquid on a stainless steel surface, representing scientific medical research into pulmonary sarcoidosis treatments. — A clinical trial presented at the CHEST 2026 Annual Meeting indicates methotrexate may be a noninferior treatment to prednisone for pulmonary sarcoidosis. AI Illustration. Upload story photo >

Live Poll

Should medical treatments prioritize alternative medications to limit long-term steroid use for patients?

At the CHEST 2026 Annual Meeting on October 18, researchers presented findings from the PREDMETH trial comparing treatment options for pulmonary sarcoidosis. The study suggests methotrexate may be a viable alternative to prednisone for patients newly diagnosed with the condition.

Why it matters

Managing pulmonary sarcoidosis is essential to prevent long-term complications like fibrosis and pulmonary hypertension. These findings provide clinicians with evidence to weigh alternative treatment paths for those who are currently treatment-naive.

In the PREDMETH trial involving 138 treatment-naive patients, methotrexate demonstrated noninferiority to prednisone for changes in percent-predicted forced vital capacity over 24 weeks. The adjusted difference was -1.17 percentage points, with these findings providing a noninferiority comparison.

The players

Rohit Gupta

The medical researcher who presented the study findings regarding sarcoidosis management at the conference.

The details

Pulmonary sarcoidosis is an inflammatory condition that can cause lasting lung damage, necessitating careful monitoring of disease activity using markers like C-reactive protein and soluble IL-2 receptor levels. Clinicians often use the Walsh and modified Walsh models, which synthesize CT imaging and pulmonary function tests, to gauge risk levels for patients. By establishing methotrexate as a noninferior alternative to prednisone, the trial offers a potential shift in standard care for newly diagnosed individuals.

October 18-21, 2026, marked the CHEST 2026 Annual Meeting held in Phoenix.
The PREDMETH trial evaluated treatment outcomes over a 24-week period.

Health Landscape

The standard of care for pulmonary sarcoidosis has historically relied on corticosteroids to manage inflammation. This trial contributes to the evolving landscape by evaluating non-steroid alternatives to help patients avoid the long-term side effects often associated with prednisone.

If you are managing pulmonary sarcoidosis, discuss the pros and cons of different long-term medication strategies with your physician. Ask about whether non-steroid options are appropriate for your specific stage of disease and overall lung function monitoring.

The takeaway

Pulmonary sarcoidosis management aims to prevent progression to fibrosis and pulmonary hypertension through consistent clinical evaluation. Patients should continue to work with their specialist to track lung function using validated models and report any changes in respiratory symptoms promptly.